PharmiWeb.com - Global Pharma News & Resources
31-Jan-2019

CD (Cluster of Differentiation) Inhibitor Pipeline Insights, 2019 Report - ResearchAndMarkets.com

The "CD (Cluster of Differentiation) Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

CD (Cluster of Differentiation) Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across CD (Cluster of Differentiation) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for CD (Cluster of Differentiation) Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for CD (Cluster of Differentiation) Inhibitor

The report assesses the active CD (Cluster of Differentiation) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. CD (Cluster of Differentiation) Inhibitor - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for CD (Cluster of Differentiation) Inhibitor

4. Comparative Analysis

5. CD (Cluster of Differentiation) Inhibitor Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. CD (Cluster of Differentiation) Inhibitor Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Affimed Therapeutics
  • MacroGenics
  • Roche
  • Tolerance Therapeutics
  • Emergent BioSolutions
  • Genentech
  • MacroGenics
  • NovImmune SA
  • Micromet Inc
  • Immunocore
  • IMC
  • Boehringer Ingelheim
  • PersonGen Biomedicine

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/znvrbv/cd_cluster_of?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190131005761/en/

Editor Details

Last Updated: 31-Jan-2019